vs
Apellis Pharmaceuticals, Inc.（APLS）与Sleep Number Corp（SNBR）财务数据对比。点击上方公司名可切换其他公司
Sleep Number Corp的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$347.4M vs $199.9M），Sleep Number Corp净利率更高（-16.8% vs -29.5%，领先12.6%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -7.8%），Sleep Number Corp自由现金流更多（$-643.0K vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -14.1%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Sleep Number是美国床具制造商，主打Sleep Number与Comfortaire品牌床垫，同时生产床架及各类床品配件。公司总部位于明尼苏达州明尼阿波利斯，除总部外，还在南卡罗来纳州和犹他州设有生产与分销网点。
APLS vs SNBR — 直观对比
营收规模更大
SNBR
是对方的1.7倍
$199.9M
营收增速更快
APLS
高出1.9%
-7.8%
净利率更高
SNBR
高出12.6%
-29.5%
自由现金流更多
SNBR
多$13.6M
$-14.3M
两年增速更快
APLS
近两年复合增速
-14.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $347.4M |
| 净利润 | $-59.0M | $-58.5M |
| 毛利率 | — | 55.6% |
| 营业利润率 | -25.6% | -13.4% |
| 净利率 | -29.5% | -16.8% |
| 营收同比 | -5.9% | -7.8% |
| 净利润同比 | -62.2% | -549.0% |
| 每股收益（稀释后） | $-0.40 | $-2.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSNBR
| Q1 26 | — | $347.4M | ||
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | $342.9M | ||
| Q2 25 | $178.5M | $327.9M | ||
| Q1 25 | $166.8M | $393.3M | ||
| Q4 24 | $212.5M | $376.8M | ||
| Q3 24 | $196.8M | $426.6M | ||
| Q2 24 | $199.7M | $408.4M |
净利润APLSSNBR
| Q1 26 | — | $-58.5M | ||
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-39.8M | ||
| Q2 25 | $-42.2M | $-25.0M | ||
| Q1 25 | $-92.2M | $-8.6M | ||
| Q4 24 | $-36.4M | $-4.7M | ||
| Q3 24 | $-57.4M | $-3.1M | ||
| Q2 24 | $-37.7M | $-5.1M |
毛利率APLSSNBR
| Q1 26 | — | 55.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 59.9% | ||
| Q2 25 | — | 59.1% | ||
| Q1 25 | — | 61.2% | ||
| Q4 24 | — | 59.9% | ||
| Q3 24 | — | 60.8% | ||
| Q2 24 | — | 59.1% |
营业利润率APLSSNBR
| Q1 26 | — | -13.4% | ||
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | -11.8% | ||
| Q2 25 | -18.6% | -0.0% | ||
| Q1 25 | -50.0% | 0.5% | ||
| Q4 24 | -12.3% | 0.7% | ||
| Q3 24 | -24.0% | 2.0% | ||
| Q2 24 | -14.7% | 1.5% |
净利率APLSSNBR
| Q1 26 | — | -16.8% | ||
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -11.6% | ||
| Q2 25 | -23.6% | -7.6% | ||
| Q1 25 | -55.3% | -2.2% | ||
| Q4 24 | -17.1% | -1.2% | ||
| Q3 24 | -29.2% | -0.7% | ||
| Q2 24 | -18.9% | -1.2% |
每股收益（稀释后）APLSSNBR
| Q1 26 | — | $-2.55 | ||
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $-1.73 | ||
| Q2 25 | $-0.33 | $-1.09 | ||
| Q1 25 | $-0.74 | $-0.38 | ||
| Q4 24 | $-0.30 | $-0.21 | ||
| Q3 24 | $-0.46 | $-0.14 | ||
| Q2 24 | $-0.30 | $-0.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $1.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | — |
| 总资产 | $1.1B | $680.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSSNBR
| Q1 26 | — | $1.7M | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | $1.3M | ||
| Q2 25 | $370.0M | $1.3M | ||
| Q1 25 | $358.4M | $1.7M | ||
| Q4 24 | $411.3M | $1.9M | ||
| Q3 24 | $396.9M | $1.6M | ||
| Q2 24 | $360.1M | $2.0M |
股东权益APLSSNBR
| Q1 26 | — | — | ||
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | $-521.3M | ||
| Q2 25 | $156.3M | $-480.7M | ||
| Q1 25 | $164.2M | $-456.8M | ||
| Q4 24 | $228.5M | $-451.6M | ||
| Q3 24 | $237.1M | $-448.8M | ||
| Q2 24 | $264.3M | $-447.0M |
总资产APLSSNBR
| Q1 26 | — | $680.1M | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $749.4M | ||
| Q2 25 | $821.4M | $804.5M | ||
| Q1 25 | $807.3M | $836.8M | ||
| Q4 24 | $885.1M | $860.8M | ||
| Q3 24 | $901.9M | $864.7M | ||
| Q2 24 | $904.5M | $883.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-643.0K |
| 自由现金流率自由现金流/营收 | -7.1% | -0.2% |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-17.7M |
8季度趋势，按日历期对齐
经营现金流APLSSNBR
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $-6.4M | ||
| Q2 25 | $4.4M | $3.8M | ||
| Q1 25 | $-53.4M | $-2.6M | ||
| Q4 24 | $19.4M | $-23.7M | ||
| Q3 24 | $34.1M | $27.3M | ||
| Q2 24 | $-8.3M | $-10.2M |
自由现金流APLSSNBR
| Q1 26 | — | $-643.0K | ||
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $-10.2M | ||
| Q2 25 | $4.4M | $369.0K | ||
| Q1 25 | $-53.4M | $-7.2M | ||
| Q4 24 | $19.3M | $-30.0M | ||
| Q3 24 | — | $24.2M | ||
| Q2 24 | $-8.4M | $-15.0M |
自由现金流率APLSSNBR
| Q1 26 | — | -0.2% | ||
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | -3.0% | ||
| Q2 25 | 2.5% | 0.1% | ||
| Q1 25 | -32.0% | -1.8% | ||
| Q4 24 | 9.1% | -8.0% | ||
| Q3 24 | — | 5.7% | ||
| Q2 24 | -4.2% | -3.7% |
资本支出强度APLSSNBR
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 1.7% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.0% | 1.2% |
现金转化率APLSSNBR
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SNBR
暂无分部数据
